InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: north40000 post# 1937

Saturday, 09/03/2016 1:39:47 AM

Saturday, September 03, 2016 1:39:47 AM

Post# of 1954

Where have we seen electro-poration before?



Other shock therapies like electroporation? AstraZeneca did just sign and agreement with inovio. I also can't help to see some similarities between Bavi and Oncosec's IL-12 currently in combination trials with Keytruda.

http://investorshub.advfn.com/boards//read_msg.aspx?message_id=116832184




Too much going on with PS Targeting.... and I'm tired of looking for past posts lol

I remember a few that specifically were all about PS Targeting patents that cover within the body and outside the body. I don't see any exclusions on the patent that it must be within the body to target flipped PS...

For example:

If some medical device would be scientifically proven to target flipped PS... .such as with electroporation or maybe something that George K. Lewis was working on.... then a patent infringement could easily be filed. George K. Lewis worked with Bartyon F. Haynes at one point as well...and his son George K. Lewis Jr. filed for some patent re: ultrasound device..

http://ctinnovations.com/story/84

.... Interesting and no more rambling here till Monday as I hope Peregrine is getting down to the exact MOA and if other medical devices are copying this MOA (unintentionally.... possibly..) then Peregrine must protect their PS Targeting IP rights.


"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.